CA2264943A1 - Procedes nouveaux - Google Patents

Procedes nouveaux Download PDF

Info

Publication number
CA2264943A1
CA2264943A1 CA002264943A CA2264943A CA2264943A1 CA 2264943 A1 CA2264943 A1 CA 2264943A1 CA 002264943 A CA002264943 A CA 002264943A CA 2264943 A CA2264943 A CA 2264943A CA 2264943 A1 CA2264943 A1 CA 2264943A1
Authority
CA
Canada
Prior art keywords
cardiovascular disease
formula
compound
effects
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002264943A
Other languages
English (en)
Inventor
Maxine Gowen
Jeremy N. Bradbeer (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CA2264943A1 publication Critical patent/CA2264943A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé nouveau, destiné à traiter des maladies cardiovasculaires chez des femmes post-ménopausiques. L'idoxifène est le composé préféré.
CA002264943A 1996-09-06 1997-09-03 Procedes nouveaux Abandoned CA2264943A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2543996P 1996-09-06 1996-09-06
US60/025,439 1996-09-06
US5066697P 1997-06-24 1997-06-24
US60/050,666 1997-06-24
PCT/US1997/015475 WO1998009619A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux

Publications (1)

Publication Number Publication Date
CA2264943A1 true CA2264943A1 (fr) 1998-03-12

Family

ID=26699738

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002264943A Abandoned CA2264943A1 (fr) 1996-09-06 1997-09-03 Procedes nouveaux
CA002264775A Abandoned CA2264775A1 (fr) 1996-09-06 1997-09-03 Methode de traitement des maladies post-menopausiques, dont l'osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002264775A Abandoned CA2264775A1 (fr) 1996-09-06 1997-09-03 Methode de traitement des maladies post-menopausiques, dont l'osteoporose

Country Status (16)

Country Link
EP (2) EP0927029A4 (fr)
JP (2) JP2002515046A (fr)
KR (2) KR20000068472A (fr)
CN (2) CN1236299A (fr)
AR (1) AR008155A1 (fr)
AU (2) AU4247397A (fr)
BR (2) BR9711676A (fr)
CA (2) CA2264943A1 (fr)
CO (2) CO4920218A1 (fr)
CZ (1) CZ76699A3 (fr)
IL (1) IL128645A0 (fr)
NO (2) NO991097L (fr)
PL (2) PL332278A1 (fr)
TR (2) TR199900504T2 (fr)
TW (1) TW411273B (fr)
WO (2) WO1998009519A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034608A1 (fr) * 1997-02-11 1998-08-13 Novo Nordisk A/S Methodes therapeutiques ou prophylactiques a l'encontre de symptomes menopausiques
GB9827121D0 (en) * 1998-12-09 1999-02-03 Orion Corp Agent for lowering endothelin levels
DE19905961A1 (de) * 1999-02-12 2000-08-17 Stefan Neubauer Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz
US6528681B2 (en) * 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260066B1 (fr) * 1986-09-11 1990-05-09 National Research Development Corporation Dérivés du tamoxifène
DE69316633T2 (de) * 1992-09-15 1998-05-20 Merrell Dow Pharma Nichtmetabolisierbare clomiphene-analoge zur behandlung von tamoxifen-resistenten tumoren
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5604248A (en) * 1994-05-05 1997-02-18 Eli Lilly And Company Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
JPH11510479A (ja) * 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis

Also Published As

Publication number Publication date
KR20000068473A (ko) 2000-11-25
AU4247397A (en) 1998-03-26
NO991096L (no) 1999-03-05
PL332038A1 (en) 1999-08-16
NO991097D0 (no) 1999-03-05
AR008155A1 (es) 1999-12-09
TW411273B (en) 2000-11-11
BR9711676A (pt) 1999-08-24
NO991097L (no) 1999-03-05
JP2002515046A (ja) 2002-05-21
TR199900506T2 (xx) 1999-07-21
WO1998009519A1 (fr) 1998-03-12
NO991096D0 (no) 1999-03-05
IL128645A0 (en) 2000-01-31
JP2002515047A (ja) 2002-05-21
AU4409797A (en) 1998-03-26
BR9711681A (pt) 1999-08-24
EP0929216A4 (fr) 2001-04-04
EP0927029A1 (fr) 1999-07-07
CA2264775A1 (fr) 1998-03-12
CZ76699A3 (cs) 1999-08-11
CO4920218A1 (es) 2000-05-29
EP0929216A1 (fr) 1999-07-21
CN1236299A (zh) 1999-11-24
PL332278A1 (en) 1999-08-30
TR199900504T2 (xx) 1999-06-21
EP0927029A4 (fr) 2001-06-13
KR20000068472A (ko) 2000-11-25
CO5070658A1 (es) 2001-08-28
CN1236313A (zh) 1999-11-24
WO1998009619A1 (fr) 1998-03-12

Similar Documents

Publication Publication Date Title
CA1337591C (fr) Composition therapeutique contenant de l'oestrogene et un anti-oestrogene
KR100278946B1 (ko) 혈청 콜레스테롤을 저하시키는데 유용한 벤조티오펜
CA2356158C (fr) Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
AU716249B2 (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
WO2000038726A1 (fr) Combinaisons d'inhibiteurs de transport de l'acide biliaire ileal et d'inhibiteurs de la proteine de transfert de l'ester de cholesteryle utilisees dans le cadre de maladies cardio-vasculaires
AU2002243411B2 (en) Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy
NZ262657A (en) Hormone replacement therapy using estrogen and antiprogestin
WO2000038722A1 (fr) COMBINAISONS D'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE L'ESTER DE CHOLESTERYLE ET D'INHIBITEURS DE LA HMG CoA-REDUCTASE UTILISEES DANS LE CADRE DE TROUBLES CARDIO-VASCULAIRES
PH26709A (en) Compositions and method of selecting contraceptions
NZ210626A (en) Multi-stage contraceptive combination
CA2264943A1 (fr) Procedes nouveaux
CA2268211A1 (fr) Controle des modulateurs recepteurs d'oestrogenes selectifs
US20020183291A1 (en) Product for treating gynecomastia
JP2000513331A (ja) 鬱病の治療におけるパロキセチン
US4956361A (en) New combination products having an antidepressant action
MXPA99002214A (en) Novel methods
WO1999000019A1 (fr) Procedes de traitement des symptomes de la vaginite atrophique et du comportement sexuel modifie chez des femmes postmenopausees
WO1999000018A1 (fr) Methodes de traitement des symptomes de troubles de la memoire, de la concentration et de la cognition chez la femme menauposee
WO1998049896A1 (fr) Methode de traitement de symptomes vasomoteurs
WO1995008329A1 (fr) Procedes de reduction du ldl cholesterol post-menopausique
NZ244997A (en) Use of melatonin derivatives for contraception

Legal Events

Date Code Title Description
FZDE Discontinued